MindBio's AI Voice Tech Hits 83% Intoxication Detection Accuracy, Eyes Commercial Pilot

MindBio Therapeutics reports up to 83% accuracy in AI-driven voice intoxication detection, surpassing some cheek swab tests, and announces a $350,000 private placement to fund its first commercial pilot.

Chicago Metrowire Staff
••Technology
MindBio's AI Voice Tech Hits 83% Intoxication Detection Accuracy, Eyes Commercial Pilot

MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) has announced that its artificial intelligence (AI)-driven voice analytics technology is nearing final product testing ahead of its first commercial pilot, with intoxication detection accuracy reaching up to 83% under certain testing conditions. The company reported that its prediction models, tested with and without sober baseline tracking, have exceeded the accuracy of some commercially available cheek swab tests. This development matters because it suggests a scalable, non-invasive alternative to traditional intoxication testing methods, with potential applications across industries such as mining, aviation, construction, and law enforcement.

MindBio plans to conduct additional human testing over the next two to three weeks before launching its first commercial pilot. The company expects its initial commercially ready product to integrate proprietary Voice AI software with its previously announced Edge AI Intoxication Detection Kiosk, initially operating in Spanish. The technology uses over 50 million data points to predict alcohol intoxication solely from the human voice, according to the company. If validated in real-world settings, this approach could enable rapid, contactless screening at scale, reducing reliance on invasive biological tests and potentially improving workplace safety and compliance.

Separately, MindBio announced a nonbrokered private placement of up to 3,888,889 units at $0.09 per unit for gross proceeds of up to CA$350,000. Each unit will consist of one common share and one-half of a common share purchase warrant, with each whole warrant exercisable at $0.16 per share for 36 months following closing. Proceeds are intended to support general working capital, annual audit and legal expenses, and OTC and CSE listing costs. The financing is modest but signals the company's focus on maintaining its public listings and funding near-term milestones as it moves toward commercialization.

For investors, the announcement offers two key signals: technical progress and capital strategy. The reported accuracy, while preliminary, positions MindBio's voice-based approach as a potential competitor to existing intoxication screening tools. The private placement, though small, provides working capital to advance the pilot and cover compliance costs. The company's shares trade on the CSE, Frankfurt, and OTCQB under the symbols MBIO, WF6, and MBQIF, respectively. As with any early-stage technology, independent validation and regulatory acceptance will be critical to commercial success. MindBio's ability to execute its testing timeline and secure pilot partners will determine whether its voice analytics platform can transition from promising prototype to adopted enterprise solution.

For a deeper look at the company, see MindBio Therapeutics Corp. and MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF). The full press release is available at https://ibn.fm/ErHN1, and ongoing updates can be found at https://ibn.fm/MBQIF. This news was distributed via TechMediaWire, part of the Dynamic Brand Portfolio at IBN.

Blockchain Registration

QR Code for Blockchain Registration